[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review].
The data and the conclusions of the Cochrane review of drug therapy for the management of cancer related fatigue (CRF) is analysed and summarized in this report. Overall, data is weakened substantially by a high degree of heterogeneity that stems primarily from the fact that fatigue is a subjective and multidimensional phenomenon Apart from erythropoietin and to some degree methylphenidate, there is no evidence that pharmacologic intervention may reduce CRF. CRF has major impact on quality of life for most patients suffering from a cancer disease. It is therefore of obvious importance to increase the focus on CRF - both in the pharmaceutical industry and in the professional-medical environment.
Pedersen
Lise
L
Palliativ Medicinsk Afdeling, Bispebjerg Hospital, DK-2400 København NV. lp02@bbh.regionh.dk
Palshof
Torben
T
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications* / Q000523:psychology / Q000628:therapy; D017374:Paroxetine / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D000697:Central Nervous System Stimulants; D004921:Erythropoietin; D006397:Hematinics; D008774:Methylphenidate; D017374:Paroxetine; D011372:Progestins; D017367:Selective Serotonin Reuptake Inhibitors